An interventional study of Empowered Relief in Chronic Pain and Cesarean Section Complications, sponsored by Stanford University. Terminated at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-06.
Sponsored by Stanford University · Not applicable, Interventional, and Treatment
unable to enroll participants with current study design
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 47 studies in Chronic Pain by Stanford University — 14 open to participants now, 18 under way, 1 of them phase 3. Chronic Pain · Stanford University.
Among the 47 studies in Chronic Pain by Stanford University, this one is the 34th largest by enrollment of the 37 interventional ones that give a count, is one of 3 that started in 2025, is one of 25 with no phase, and was the 42nd registered.
3,230 studies on the registry are indexed under Chronic Pain; 728 are open to participants now.
Browse Chronic Pain studies →14 of the 47 studies in Chronic Pain by Stanford University are open now, in 1 country. Recruiting first, the newest first:
Stanford University · Sites in United States
Ages 18+ · Women only
Stanford University · Sites in United States
Ages 18+
Stanford University · Sites in United States
Ages 18–75
Stanford University · Sites in United States
Ages 18–65
Stanford University · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 486 Chronic Pain studies recruiting now, 239 (49%) set no upper age limit and 173 (36%) stop at 75 or younger; 43 take children under 18; 64 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
47 studies; the count open now beside each. This study's row is marked.
First in 1998; this study’s year is marked. 3 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1 is below the median of 60 across 2,388 interventional studies indexed under Chronic Pain.
Median enrollment 80 across the 37 interventional studies, 259 across the 10 observational. Of the 22 that completed or were terminated, 10 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
Stanford University is the lead sponsor of 2,171 studies on the registry; 425 are open to participants now.
Of its 268 completed or terminated interventional studies of FDA-regulated products, 207 (77%) have results posted.
9 of the studies in Chronic Pain by Stanford University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06867757Stanford UniversityTargeted Realtime Assessment of Chronic Pain in Youth | 2026-11 |
| NCT06317636Stanford UniversityPropofol-Enhanced Assessment of Ketamine for Chronic Pain and Depression | 2026-11 |
| NCT04546685Stanford UniversityVirtual 1-Session Spanish "Empowered Relief" Group Intervention for Chronic Pain | 2026-12-31 |
| NCT07832240Stanford UniversityEmpowered Relief for Severe Pain After Cesarean Delivery During the Inpatient Period | 2027-01-15 |
| NCT07799883Stanford UniversityReducing Chronic Pain Following Cesarean Delivery | 2027-01-31 |
Add all 9 to your calendar (.ics) → With an account.
Among the 47 studies in Chronic Pain by Stanford University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to study the effect of a pain relief skills session (Empowered Relief) on chronic pain incidence at 12 weeks post cesarean delivery.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants will attend an Empowered Relief session at the beginning of the study period. Empowered Relief is a 2-hour one session pain relief skills intervention that is delivered to patients by a certified instructor using a standardized treatment manual and slide deck. Content includes completion of a pain survey, pain neuroscience education, information on pain and stress responses, experiential exercises, information on three core pain management skills, completion of a personalized plan for empowered relief, and receipt of a binaural app for daily use. Standard of care will be maintained for all participants, and supplemented with Empowered Relief. Pain management is not a factor for inclusion/exclusion criteria and patients will continue their pain management as prescribed and directed by their provider
Behavioral: Empowered Relief
Participants will follow their current standard of care.
The participants will attend a pain relief skills intervention (Empowered Relief). The two-hour session is delivered by a certified instructor and includes pain neuroscience education, 3 core pain management skills, experiential exercises, completion of a personalized plan for empowered relief. Participants download a binaural relaxation audio file for daily use.
Also known as: 1-Session Pain Relief Skills Intervention
Percentage of participants registering for Empowered Relief session
Time frame: Baseline (up to 1 week)
Percentage of participants attending Empowered Relief session
Time frame: Treatment (up to 2 weeks)
Participant Satisfaction Scale Score
Participant satisfaction will be measured using a 7 item questionnaire (scale ranges from 0 - 42, higher ratings represent greater satisfaction with the treatment).
Time frame: 1 - 2 weeks Post treatment
Participant Treatment Skills Use Scale Score
Participant treatment skills use will be measured with a 5 items questionnaire (scale ranges from 0 - 25, higher ratings represent increased time using treatment).
Time frame: 4 - 6 weeks Post Treatment
Change from baseline in PROMIS Pain Interference 8a scale score
Participants complete Patient Reported Outcomes Measurement Outcomes System (PROMIS) Pain Interference 8a questionnaire, an 8-item scale assessing pain interference with life enjoyment, concentration, and daily activities over the past 7 days. (Score range 8 - 40, higher scores represent a greater degree of pain interference).
Time frame: Baseline, Week 6
Change from baseline in PROMIS Pain Intensity 3a scale score
Participants complete PROMIS Pain Intensity 3a questionnaire, a 3-item scale assessing average pain intensity for the past 7 days. (Score range 3 - 15, higher score represents a greater degree of pain intensity)
Time frame: Baseline, Week 6
Change from baseline in Pain Catastrophizing Scale Score
Participants complete Pain Catastrophizing questionnaire, a 13-item scale assessing an individual's pain experience (Score range 0 - 52, higher score represents a greater degree of pain catastrophizing)
Time frame: Baseline, Week 6
Change from baseline in PEG scale score (composite)
Participants complete thrice weekly Pain, Enjoyment, General Activity Scale (PEG) questionnaire, a 3-item scale assessing pain interference and intensity via SMS. (Score range 0 - 30, higher score represents a greater degree of pain intensity/interference)
Time frame: From enrollment to the end of study completion at 6 weeks
Change from baseline in PEG scale score (pain interference)
Participants complete thrice weekly PEG questionnaire, to assess pain interference via SMS. (Score range 0 - 20, higher score represents a greater degree of interference)
Time frame: From enrollment to the end of study completion at 6 weeks
Change from baseline in PEG scale score (pain intensity)
Participants complete thrice weekly PEG questionnaire to assess pain intensity, via SMS. (Score range 0 - 10, higher score represents a greater degree of pain intensity)
Time frame: From enrollment to the end of study completion at 6 weeks
Response rate to individual items of the PEG scale score via SMS
Participant percentage responding to items of the thrice weekly PEG questionnaire, a 3-item scale assessing pain interference and intensity via SMS. (Score range 0 - 3; higher scores indicate higher response rate)
Time frame: From enrollment to the end of study completion at 6 weeks
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices).
Supporting information: Study protocol
Time frame: Beginning 9 months and ending 36 months following article publication.
Access criteria: Wish whom? Investigators whose proposed use of the data has been approved by an independent review committee ("learned intermediary") identified for this purpose. For what types of analysis? For individual participant data meta-analysis By what mechanism will data be made available? Proposals may be submitted up to 36 months following article publication. After 36 months the data will be available in our University's data warehouse but without investigator support other than deposited metadata. Information regarding submitting proposals and accessing data may be found at (Link to be provided).
Ran from Sep 2025 to primary completion in Sep 2026, 12 months.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 6, 2026: primary completion Dec 2026 → Sep 2026 and completion Dec 2026 → Sep 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
unable to enroll participants with current study design
unable to enroll participants with current study design
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is terminated, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.